{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-224214","form_type":"8-K","ticker":"FBRX","cik":"0001419041","company_name":"Forte Biosciences, Inc.","filed_at":"2026-05-14T20:42:13+00:00","discovered_at":"2026-05-14T20:43:00.243678+00:00","generated_at":"2026-05-14T20:44:00.199104+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Forte Q1 net loss $22.1M; FB102 gets FDA Fast Track; raised $172.5M in April","bullets":["Q1 2026 net loss $22.1M ($1.24 per share); cash $58.2M at March 31, 2026.","FB102 received FDA Fast Track Designation for celiac disease; phase 2 topline results expected in 2026.","Phase 1b vitiligo data expected shortly; alopecia areata data readout in 2026.","R&D expenses rose to $20.5M from $12.7M YoY due to increased clinical and preclinical costs.","In April 2026, raised $172.5M gross via equity offering, issuing 6.6M common shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-224214","json":"https://secwatch.observer/filing/0001193125-26-224214.json","markdown":"https://secwatch.observer/filing/0001193125-26-224214.md","text":"https://secwatch.observer/filing/0001193125-26-224214.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1419041/000119312526224214/0001193125-26-224214-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1419041/000119312526224214/d95486d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T20:44:00.199104+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8443cefbc2c4f4d1f771f6d094967f7829ff8bba","claim":"Forte Biosciences, Inc. reported the quarter ended March 31, 2026 results: net income Net loss per share - basic and diluted $ (1.24 ), EPS $(1.24).","evidence_excerpt":"Forte Biosciences, Inc. issued a press release reporting its financial results for the quarter ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1419041/000119312526224214/0001193125-26-224214-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2026"},{"label":"Net income","value":"Net loss per share - basic and diluted $ (1.24 )"},{"label":"EPS","value":"$(1.24)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}